Breaking News, Financial News

Eurand 1Q08

Eurand

1Q Revenues: $24.9 million (+24%)

1Q Loss: $1.6 million (loss of $1.2 million in 1Q07)

Comments: Product sales were $32.0 million (+17%). Royalties were $2.7 million (+103%). R&D expenses were $7.1 million (+21%). Revenues include $1.4 million from the Source CF acquisition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters